LDL-C and TC Mediate the Risk of PNPLA3 Inhibition in Cardiovascular Diseases - Takeaways - MDSpire

LDL-C and TC Mediate the Risk of PNPLA3 Inhibition in Cardiovascular Diseases

  • By

  • Genshan Zhang

  • Wei Jiang

  • Fangxun He

  • Jie Fu

  • Xiangshang Xu

  • Xuelai Luo

  • Zhixin Cao

  • April 18, 2024

  • 0 min

Share

  • 1

    PNPLA3 inhibition is linked to increased risks of coronary atherosclerosis, coronary heart disease, and myocardial infarction.

  • 2

    Blood LDL-C and TC mediate a significant portion of the associations between PNPLA3 inhibition and major cardiovascular diseases.

  • 3

    ARO-PNPLA3 effectively reduces liver fat in patients with metabolic dysfunction-associated steatotic liver disease.

  • 4

    The long-term effects and safety of ARO-PNPLA3 remain uncertain despite promising Phase I clinical trial results.

  • 5

    Mendelian randomization analysis was utilized to explore the causal relationship between PNPLA3 inhibition and cardiovascular outcomes.

Original Source(s)

LDL-C and TC Mediate the Risk of PNPLA3 Inhibition in Cardiovascular Diseases

  • by Genshan Zhang, Wei Jiang, Fangxun He, Jie Fu, Xiangshang Xu, Xuelai Luo, Zhixin Cao

  • April 18, 2024

Related Content

High Seroprevalence of Hepatitis E Virus Among Patients With Hepatitis B and Those With Hepatitis of Unknown Etiology in Central Vietnam

Lipid metabolism-MAFLD crosstalk: mechanisms and therapy

Combo Therapy for Psoriasis With Obesity

A phase 3b trial tests ixekizumab plus tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight.